Trial Profile
A Prospective, Multi-Centric, Randomized, Double-Blind, Parallel, Phase-III Study to Assess Efficacy of PMZ-2010 as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Shock Treatment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Sep 2022
Price :
$35
*
At a glance
- Drugs Centhaquine (Primary)
- Indications Hypovolaemic shock
- Focus Registrational; Therapeutic Use
- Sponsors Pharmazz
- 13 Sep 2022 According to Pharmazz media release, data from this trial was presented at the Military Health System Research Symposium (MHSRS).
- 01 Jun 2021 Results evaluating the efficacy of centhaquine in patients with hypovolemic shock published in the Drugs
- 01 Jun 2021 Results presented in a Pharmazz media release.